4D Molecular Therapeutics Inc
FDMT
NASDAQ
Biotechnology
$12.19
USD
+0.54 (+4.64%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $609.02M
Volume 773.7K
Revenue
$88.24M
TTM
+383560.9%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-160.90M
TTM
+8.8%
YoY
Operating Cash Flow
$-129.45M
TTM
+15.5%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.1 | 85.1 | 3.0 |
YoY Growth | -50.0% | +200.0% | +2900.0% | +8508900.0% | +21664.3% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.1 | 85.1 | 3.0 |
Selling, General & Administrative | 12.9 | 11.5 | 11.8 | 12.8 | 11.7 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 53.6 | 59.5 | 61.3 | 70.4 | 76.7 |
Operating Income | -53.6 | -59.5 | -61.2 | 14.7 | -73.6 |
EBITDA | -52.6 | -58.3 | -59.9 | 15.9 | -72.4 |
Other Income / Expense | 0.1 | -0.1 | -0.0 | -0.0 | -0.0 |
Total Other Income / Expense | 5.6 | 4.8 | 4.3 | 4.7 | 4.9 |
Income Before Income Taxes | -48.0 | -54.7 | -56.9 | 19.4 | -68.8 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -48.0 | -54.7 | -56.9 | 19.4 | -68.8 |
Consolidated Net Income / Loss | -48.0 | -54.7 | -56.9 | 19.4 | -68.8 |
Net Income Attributable to Common Shareholders | -48.0 | -54.7 | -56.9 | 19.4 | -68.8 |
Basic EPS | -$0.86 | -$0.98 | -$1.01 | $0.30 | -$1.01 |
Diluted EPS | -$0.86 | -$0.98 | -$1.01 | $0.30 | -$1.01 |
Basic Shares Outstanding | 55.7M | 55.9M | 56.1M | 63.9M | 68.1M |
Diluted Shares Outstanding | 55.7M | 55.9M | 56.1M | 63.9M | 68.1M |